GLP-1 & GIP under the lens: HRMS strategies for synthetic peptide profiling

Synthetic peptides like GLP-1 analogs (e.g., semaglutide, tirzepatide) present analytical challenges due to complex modifications and potential degradation products. High resolution accurate mass spectrometry (HRMS) offers the sensitivity, resolution, and mass accuracy needed for confident sequence confirmation and impurity profiling.

In this Tech Talk, attendees will discover how integrated workflows from high-throughput screening using the INTACT Mass App to detailed degradation characterization with UNIFI streamline synthetic peptide analysis, support quality attribute monitoring, and ensure regulatory compliance.

Certificate of attendance

• If you attend the live TechTalk, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. 
• If you view the on-demand TechTalk, you can request a certificate of attendance by emailing [email protected].

TechTalk details

• Cost: Free to attend
• Location: Online
• Duration: 20 minutes

Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on-demand recording once it becomes available.

Who should attend?

This event is perfect for:

• Bioanalytical scientists
• Pharmaceutical R&D researchers
• QC/QA laboratory managers
• Contract Research Organisation (CRO) scientists
• Mass spectrometry specialists

What will this webinar cover?

• The advantages of high resolution accurate mass spectrometry (HRMS) over nominal mass systems for resolving near-isobaric impurities and peptide variants.
• How high-throughput screening tools enable rapid mass confirmation, sequence verification, and routine purity reporting.
• Strategies for comprehensive qualitative analysis and tracking of forced degradation products.

Presenter: Jonathan Fox (Biologics Consulting Scientist, Waters Corporation)

Jonathan Fox is a Biologics Consulting Scientist at Waters Corporation, specializing in advanced high resolution accurate mass spectrometry (HRMS) applications for biopharmaceutical research and development. With extensive expertise in biotherapeutic characterization, analytical chemistry, and liquid chromatography-mass spectrometry (LC-MS) workflows, he focuses on developing innovative solutions for complex molecules, including synthetic peptides, oligonucleotides, and therapeutic proteins. He works closely with pharmaceutical and biotech organizations to optimize quality attribute monitoring and impurity profiling strategies.